Skip to main content
OpenTrials
Completed

NCT Number: NCT00357383

Study of the Ocular Safety After Repeated Instillations of T1225 1% or 1.5% Eye Drops in Healthy Volunteers

To evaluate the ocular tolerance of T1225 1% and 1.5% eye drops versus vehicle after one instillation twice-daily (morning and evening), in one eye, during 3 days (from Day 0 to Day 2).

To assess azithromycin tear, conjunctiva and plasmatic concentrations, after a 3-day treatment period

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

About this study

The aim of the present study was to compare ocular tolerance and safety after repeated instillations of T1225 1% and 1.5% eye drops and vehicle and to assess the residual azithromycin concentrations in tear, ocular conjunctiva and plasma samples, approximately 12 hours after the last Investigational Medicinal Product instillation.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female aged from 18 to 45 years old;
  • Written informed consent;
  • Healthy volunteers without any subjective ocular symptom;
  • Normal ocular examination in both eyes (corrected visual acuity >= 6/10, normal slit lamp examination, tear prism height > 0.1mm, tear break-up time (BUT) >= 10 seconds, lissamine green test score < 4);
  • Registered, or agreed to be registered, in the national register of healthy volunteers

Exclusion criteria

  • Ocular trauma, infection or inflammation within the last 3 months;
  • number of corneal stained punctuations Ocular trauma, infection or inflammation within the last 3 months;
  • number of corneal stained punctuations >= 5;
  • blepharitis, conjunctivitis, uveitis;
  • contact lenses;
  • topical ocular treatment within the last month;
  • ocular laser within the last 3 months;
  • ocular surgery, including LASIK and PRK, within the last 12 months;
  • systemic macrolide within the last month;
  • medication during the study (except: paracetamol and contraceptives).

Treatment and study plan

Azithromycin (T1225)

Drug

Primary outcomes

  1. Ocular pharmacokinetic in tears

Secondary outcomes

  1. Tolerance

Sponsors and collaborators

Lead sponsor

Laboratoires Thea

Industry

Registry information

Important dates

Study start
2002
Study completion
2002
First posted
Jul 27, 2006
Registry last updated
Jul 27, 2006

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.